The Use of Statins in the Treatment and Prevention of Atrial Fibrillation. Issue 5 (September 2016)

• Record Type: Journal Article
• Authors: Groves, Donald; Mihos, Christos G.; Larrauri-Reyes, Maiteder; Santana, Orlando
• Is Part Of: Cardiology in review. Volume 24:Issue 5(2016)
• Publication Date: 2016-09
• Subjects: hydroxy-methyl-glutaryl-CoA-reductase inhibitors -- atrial fibrillation -- statins -- pleiotropic effects; Cardiology -- Periodicals; 616.12
• DOI: 10.1097/CRD.0000000000000090
• Languages: English
• ISSNs: 1061-5377

Abstract

Abstract : The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia and in the primary and secondary prevention of cardiovascular and cerebrovascular diseases. Statins have also been demonstrated to confer secondary pleiotropic benefits in a variety of other disease processes, including a potential advantage in treating and preventing atrial fibrillation. These effects are primarily due to the up-regulation of endothelial nitric oxide synthase activity and a decrease in nicotinamide adenine dinucleotide phosphate oxidase production, which leads to downstream effects that improve the electromechanical function of atrial and myocardial tissue. The following serves as a focused and updated review of the published clinical data regarding the pleiotropic effects of statins in atrial fibrillation.